Company Description
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States.
Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy.
The company also develops LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy.
In addition, it is developing LX1001, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease.
The company has license agreement with Cornell University to conduct of the Phase 1/2 clinical trial of LX1001, as well as support the development of LX1004 program; research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate.
The company was founded in 2017 and is headquartered in New York, New York.
| Country | United States |
| Founded | 2017 |
| IPO Date | Nov 3, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 72 |
| CEO | R. Townsend |
Contact Details
Address: 345 Park Avenue South, 6th Floor New York, New York 10010 United States | |
| Phone | 212 547 9879 |
| Website | lexeotx.com |
Stock Details
| Ticker Symbol | LXEO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $11.00 |
| CIK Code | 0001907108 |
| CUSIP Number | 52886X107 |
| ISIN Number | US52886X1072 |
| Employer ID | 85-4012572 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| R. Nolan Townsend | Chief Executive Officer and Director |
| Dr. Eric Adler M.D. | Chief Medical Officer and Head of Research |
| Dr. Jose Manuel Otero Ph.D. | Chief Technical Officer |
| Dr. Ronald G. Crystal M.D. | Co-Founder, Chief Scientific Advisor and Member of Scientific Advisory Board |
| Dr. Kyle Rasbach Ph.D., Pharm.D. | Chief Financial Officer |
| Jenny R. Robertson J.D. | Chief Legal Officer |
| Jordan M. Baumhardt Ph.D. | Vice President of Corporate Development |
| Dr. Sandi See Tai M.D. | Chief Development Officer |
| Leslie DiRisio | Senior Vice President of Development Operations |
| Ryan McHenry | Vice President and Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2025 | 10-Q | Quarterly Report |
| Aug 14, 2025 | 8-K | Current Report |
| Aug 14, 2025 | SCHEDULE 13G | Filing |
| Aug 7, 2025 | SCHEDULE 13G/A | Filing |
| Jul 1, 2025 | 424B3 | Prospectus |
| Jun 30, 2025 | EFFECT | Notice of Effectiveness |
| Jun 30, 2025 | 8-K | Current Report |
| Jun 26, 2025 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Jun 13, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Jun 5, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |